Drug Report History
Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.
The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.
| Version v5-FR | Version v5-FR | |
|---|---|---|
| Language | French | French |
| Date Updated | 2025-04-08 | 2025-04-08 |
| Drug Identification Number | 02294222 | 02294222 |
| Brand name | MYCAMINE | MYCAMINE |
| Common or Proper name | Mycamine | Mycamine |
| Company Name | ASTELLAS PHARMA CANADA INC | ASTELLAS PHARMA CANADA INC |
| Ingredients | MICAFUNGIN SODIUM | MICAFUNGIN SODIUM |
| Strength(s) | 50MG | 50MG |
| Dosage form(s) | POWDER FOR SOLUTION | POWDER FOR SOLUTION |
| Route of administration | INTRAVENOUS INTRAVENOUS | INTRAVENOUS INTRAVENOUS |
| Packaging sizes (GTIN) | (See additional packaging sizes) | (See additional packaging sizes) |
| Additional packaging sizes | 10mL Vial Pk | 10mL Vial Pk |
| ATC code | J02AX | J02AX |
| ATC description | ANTIMYCOTICS FOR SYSTEMIC USE | ANTIMYCOTICS FOR SYSTEMIC USE |
| Reason for shortage | Other (Please describe in comments) | Other (Please describe in comments) |
| Anticipated start date | 2025-02-11 | 2025-02-11 |
| Actual start date | 2025-02-11 | 2025-02-11 |
| Estimated end date | Unknown | Unknown |
| Actual end date | 2025-03-20 | 2025-03-20 |
| Shortage status | Resolved | Resolved |
| Tier 3 Status | No | No |
| Company comments | Market Authorization Transfer (MAT) of Mycamine to Sandoz Canada occurred on March 20, 2025 | Market Authorization Transfer (MAT) of Mycamine to Sandoz Canada occurred on March 20, 2025 |
| Health Canada comments |